Herein, we propose to investigate in more detail the effect of MeDi in lowering the serum levels of AGEs and in promoting the activity/expression of key molecules involved in the Nrf2 pathways, in order to have a clear molecular target that will provide a defined measure of the efficacy of MeDi and a molecular correlation with the progression of retinal diseases. This evidence concerns the gene NFE2L2 and Abnormal retinal morphology.